Compare Incyte Corporation (INCY) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Intuitive Surgical, Inc. — how do they compare? Incyte Corporation trades at $113.17 (market cap $22.85B), while Intuitive Surgical, Inc. trades at $425.85 (market cap $146.76B). The key difference: Intuitive Surgical, Inc. is far larger — about 6.4× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Intuitive Surgical, Inc. for 84 Days on average.
| INCY | ISRG | |
|---|---|---|
Market Cap | $22.85B | $146.76B |
Volume | 1,927,029 | 2,529,814 |
Sector | Health | Health |
52-Week High | $129.93 | $592.85 |
52-Week Low | $83.80 | $332.02 |
Typical Hold Time | 33 Days | 84 Days |
Enterprise Value | $18.35B | $141.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Intuitive Surgical (ISRG) trades at $424.58, up 2.43% with strong bullish momentum. The stock shows robust fundamentals with revenue growing from $6.2B in 2022 to $10.1B in 2025 and net profit margins exceeding 28%. Recent earnings consistently beat expectations, with Q2 2026 EPS of $2.80 surpassing the $2.48 forecast. Technical indicators show bullish moving averages with support at $410 and resistance at $419. Analyst consensus remains strongly positive with 70% buy ratings and a $480.78 price target.
ISRG maintains a dominant position in robotic surgery with expanding international growth offsetting China headwinds. The primary investment opportunity lies in continued procedure growth and da Vinci 5 adoption, though risks include competitive pressures and affordability concerns. With strong cash flow generation and institutional support, the stock presents upside potential despite premium valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
